Should I do my own research into available clinical trials? Are clinical trials only options of last resort? Will my insurance pick up the cost of a clinical trial?
Does my doctor get paid if I participate in a trial? Will I have to travel to participate in a clinical trial? What is randomization, and can I avoid it? Could I wind up receiving a placebo sugar pill instead of treatment? How would I know if I could get a placebo? Are clinical trials as safe as standard treatments? How do I sign up for a trial? What is a trial protocol?
How often are results checked? How are results used? Will I find out the results? General Information About Clinical Trials. Some common types of exclusion criteria you might see include items such as:. Serious side effects from prior treatment, such as cardiomyopathy heart damage Until shown otherwise, there is always the concern that new treatment agents might make the condition worse.
Prior cancer treatment within a short time frame Since cancer treatments can take a few weeks or even more time to show responses, it might not be possible to determine if the previous treatment or the experimental one was responsible for a response. No measurable tumors Most trials are set up to measure tumor shrinkage, or time to tumor size progression, as a result of treatment.
Central nervous system involvement Because many of the drugs used to treat sarcomas are thought to not cross from the bloodstream into the brain or spinal cord the blood-brain barrier , metastases in the central nervous system may make a patient ineligible for a trial.
Females who are pregnant or breast-feeding Experimental cancer treatments are never assumed to be safe for developing babies, as they are usually intended to stop cell division or kill cells outright. Active infections Most anti-cancer treatment agents suppress the immune system, so having an active infection at the start of treatment could be very dangerous. Other medical conditions that could affect the health of the patient If your physician feels that your health could be compromised if you were on the trial due to other medical conditions you have, you should not be enrolled on it.
Trials can be sponsored by a variety of institutions. Government In the U. Cooperative Groups These groups are consortiums of hospitals that specialize in doing research on cancer. Single Institution These are universities and hospitals that set up their own trials. Individual These are specialist physicians who have a research interest and a large enough patient population to set up a trial and get results within a reasonable time frame.
Companies Companies sponsor clinical trials to show that their new treatment agent works better than existing treatments, which allows them to get approval for their agent. Summary of Pros and Cons of Clinical Trials. Locations The trial is likely to be done by specialists or at specialist institutions where you can get the best care. You may have to travel for at least part of the treatment.
Medical Tests You will be more closely followed by your oncologist than if you are on a standard treatment, which can provide better information on how well the treatment is doing as well as controlling side effects. You may need to do more doctor visits and more types of tests than with a standard treatment.
You might not get the experimental treatment, and it could turn out that the treatment you received, experimental or standard, was not the superior arm. Involvement in Treatment Participants have made an active choice in their treatment and are often more aware of their options.
Randomization may make some people feel that they have less control over their treatment. Efficacy You will be getting at least the standard treatment, and may be getting a better treatment. The trial may not benefit you personally. Helping Others Clinical trials are the best way to improve treatment for people diagnosed with sarcoma in the future. There is no downside to helping others; remember that if a treatment works now, it is because previous patients enrolled in past clinical trials.
Where to Find Clinical Trials. Center Watch — Search for clinical trial listings in their database ClinicalTrials. Genetic Testing with 23andMe. Find a Sarcoma Expert We offer a list of sarcoma centers around the world to help you find sarcoma experts in your area.
Sarcoma Alliance E. Search Site Search. Site design by Endeavor Marketing Communications. This website uses cookies to give you the most relevant experience. Manage consent. Close Privacy Overview This website uses cookies to improve your experience while you navigate through the website.
Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies.
But opting out of some of these cookies may affect your browsing experience. Necessary Necessary. Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously. The cookie is used to store the user consent for the cookies in the category "Analytics". The cookie is used to store the user consent for the cookies in the category "Other.
The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is used to store the user consent for the cookies in the category "Performance". It does not store any personal data. Some may The purpose of this comparative effectiveness study is to evaluate functional outcomes, toxicities, and local control in patients with pelvic bone sarcomas treated with surgery, PT, and CIRT.
The purpose of this study is to test the safety and effectives of ramucirumab in combination with other chemotherapy in the treatment of relapsed, recurrent, or refractory synovial sarcoma SS in children and young adults.
This trial is part of the CAMPFIRE master protocol which is a platform to accelerate the development of new treatments for pediatric and young adult participants with cancer. Your participation in this trial could last 12 months or longer, depending on how you and your tumor respond. The purpose of this study is to retrospectively review the imaging findings of the uterine leiomyosarcoma and compare with those of atypical leiomyoma.
The primary objective of the study is to compare outcomes of patients undergoing sarcoma reconstructive surgery using fluorescence angiography with patients undergoing sarcoma reconstructive surgery without fluorescence angiograph. The purpose of this phase Ib trial studies the side effects of MDM2 inhibitor AMG and radiation therapy in treating patients with soft tissue sarcoma.
MDM2 inhibitor AMG may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving MDM2 inhibitor AMG and radiation therapy before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.
The purpose of the phase 1b portion is to evaluate safety and tolerability and determine a recommended phase 2 dose for TRC when added to standard dose pazopanib in patients with advanced soft tissue sarcoma. This is a Phase II, multicenter, open-label, single arm, 2-stage study of tazemetostat mg BID administered orally in continuous 28 day cycles.
Screening of subjects to determine eligibility for the study will be performed within 21 days of the first planned dose of tazemetostat. Radiation therapy uses high energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as ifosfamide and doxorubicin hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Pazopanib hydrochloride may stop the CMB is a novel approach designed to stimulate the body's immune system to fight the spread and growth of cancer in patients whose tumors express the NY-ESO-1 protein. The purpose of this study is to determine the efficacy and safety of aldoxorubicin in subjects with metastatic, locally advanced, or unresectable soft tissue sarcomas.
This is a study of TRC in combination with standard dose pazopanib compared to single agent pazopanib in patients with angiosarcoma not amenable to curative intent surgery e. This study is being done to collect clinical data and store samples of your blood and tissue for current and future research studies on sarcoma.
Sapanisertib and pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. This study is being done to see if MORAb increases the effectiveness of the chemotherapies gemcitabine and docetaxel in people with metastatic Soft Tissue Sarcoma. This randomized phase III trial studies combination chemotherapy to see how well it works compared to combination chemotherapy with topotecan hydrochloride in treating patients with non-metastatic extracranial Ewing sarcoma.
Drugs used in chemotherapy, such as vincristine sulfate, doxorubicin hydrochloride, cyclophosphamide, ifosfamide, etoposide, and topotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug combination chemotherapy may kill more tumor cells.
It is not yet known whether combination chemotherapy is more effective with topotecan hydrochloride in treating Ewing sarcoma. The purpose of this study is to compare the clinical application of two emerging magnetic resonance MR imaging modalities which Mayo Clinic has the technical capability of using, by adding them at the same time that standard imaging is done for patients receiving treatment for Ewing Sarcoma , Rhabdomyosarcoma and soft tissue sarcoma.
The purpose of this study is to evaluate the side effects of talimogene laherparepvec and radiation therapy to see how well they work in treating patients with newly diagnosed soft tissue sarcoma that can be removed by surgery. Biological therapies, such as talimogene laherparepvec, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing. Radiation therapy uses high energy x-rays, photons.
Giving talimogene laherparepvec and radiation therapy may work better in treating patients with soft tissue sarcoma. The purpose of this research is to determine whether circulating tumor DNA, RNA or proteins can be detected in the blood of patients with sarcoma. We are also interested in learning if these levels change over time while receiving chemotherapy. Patients with advanced sarcoma who will receive chemotherapy will be asked to participate.
Study participation involves blood-draws of approximately 4 tablespoons of blood at each of 4 separate time-points as well as access to archived tumor tissue, or fresh tumor tissue at the time of clinically indicated biopsy or surgery. We propose conducting a single arm, prospective study to evaluate the efficacy and safety of a preoperative hypofractionated course, The biologic equivalent dose of this regimen is We hypothesize a 15 fraction hypofractionated radiation therapy course will be associated with equivalent short term toxicity The purpose of this study is to evaluate the safety and effectiveness of AL catequentibub, anlotinib hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma ASPS , leiomyosarcoma LMS , and synovial sarcoma SS.
Two-thirds of the participants will receive AL, one-third of the participants will receive IV dacarbazine. This is a randomized, multicenter, double-blind, placebo-controlled, Phase study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately total patients will be randomized to study treatment selinexor or placebo.
This phase III trial compares the effect of vinorelbine with vincristine, dactinomycin, and cyclophosphamide VAC followed by vinorelbine and cyclophosphamide versus VAC followed by vinorelbine and cyclophosphamide for the treatment of high risk rhabdomyosarcoma. Chemotherapy drugs, such as vinorelbine, vincristine, dactinomycin, and cyclophosphamide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Giving vinorelbine and VAC may kill more tumor cells. This randomized pilot clinical trial is studying the side effects and how well giving temozolomide and cixutumumab together with combination chemotherapy works in treating patients with metastatic rhabdomyosarcoma. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Giving temozolomide and cixutumumab together with The purpose of this study is to determine the efficacy of pembrolizumab in patients with advanced sarcomas. Pazopanib is FDA approved as a second line and beyond treatment for metastatic soft tissue sarcoma.
There is a population of elderly and debilitated soft tissue sarcoma patients that are not fit for standard first line chemotherapy that is doxorubicin based. As pazopanib is well tolerated with minimal side effects, the investigators propose a phase II study to evaluate pazopanib as a first-line agent in patients with non-resectable or metastatic disease who are not candidates for cytotoxic chemotherapy.
The purpose of this study is to evaluate olaparib and temozolomide in treating patients with uterine leiomyosarcoma LMS that has spread to other places of the body or cannot be removed by surgery.
Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Safety was analysed in all patients who started their allocated treatment. This trial is registered with ClinicalTrials. Findings: Between Jan 18, and April 10, , patients were enrolled, of whom were randomly assigned to each group.
0コメント